

SUPPLEMENTARY MATERIAL

	Total (257)	In the first attempt		P value	After multiple attempts		P value
		Tolerate (n=133)	LC (n=124)		Tolerate (n=233)	Refractory (n=24)	
Age (years)	48 (40 - 61) (n=257)	50.00 (40.00 – 61.00) (n=133)	48.00 (40.00 – 59.25) (n=124)	0.9645	48.00 (40.00 – 61.00) (n=233)	51.00 (42.75 - 62.50) (n=24)	0,2232
Female gender (%)	71.98 (n=257)	75.19 (n=133)	68.55 (n=124)	0.2362	72.53 (n=233)	66.37 (n=24)	0.5423
BMI ≤ 30 (%)	70.64 (n=109)	80.00 (n=60)	59.18 (n=49)	0.0175	73.20 ((n=97)	50.00 (n=12)	0.0960
Atopy (%)	6.64 (n=256)	8.33 (n=132)	4.84 (n=124)	0.2617	7.33 (n=232)	0.00 (n=24)	0.1699
Thyroid disease (%)	14.45 (n=256)	15.15 (n=132)	13.71 (n=124)	0.7430	14.22 (n=232)	16.67 (n=24)	0.7459
Other autoimmune diseases (%)	13.28 (n=256)	16.67 (n=132)	9.68 (n=124)	0.0996	13.79 (n=232)	8.33 (n=24)	0.4530
Eosinophil count (x10 ³ /microL)	0.19 (0.10 - 0.31) (n=238)	0.17 (0.10 – 0.31) (n=122)	0.20 (0.13 – 0.32) (n=116)	0.0771	0.20 (0.10 – 0.32) (n=217)	0.15 (0.10 – 0.27) (n=21)	0.4163
Baseline Total IgE (KU/L)	153.00 (52.85 - 357) (n=219)	136.00 (33.00 – 345.00) (n=113)	164 (63.25 – 371.75) (n=106)	0.1284	151 (51.30 – 349.00) (n=197)	203.50 (62.03 – 416.00) (n=22)	0,5848
Baseline CRP (mg/dL)	0.69 (0.17 - 2.10) (n=177)	0.68 (0.13 – 1.79) (n=89)	0.83 (0.21 – 2.29) (n=88)	0.6709	0.61 (0.17 - 1.85) (n=160)	1.79 (1.06 - 6.23) (n=18)	0,0030
Baseline ESR (mm/h)	9.00 (5.00 - 17.00) (n=176)	9.00 (4.00 – 16.00) (n=85)	9.00 (5.00 – 17.50) (n=91)	0.8845	9.00 (5.00 - 17.00) (n=156)	9 .00(4.75 - 19.25) (n=20)	0,9832
Baseline TSH (μIU/mL)	2.18 (1.36 - 3.13) (n=206)	1.91 (1.29 – 2.43) (n=104)	2.30 (1.58 – 3.31) (n=102)	0.1151	2.14 (1.35 - 3.06) (n=188)	3.02 (1.70 - 4.51) (n=18)	0,0807
Baseline Anti-TPO(UI/ml)	10 (9.00 - 27.00) (n=160)	10.00 (9.00 – 30.73) (n=81)	10.00 (9.00 – 27.00) (n=79)	0.6456	10.00 (9.00 - 27.00) (n=150)	25.50 (6.33 - 83.50) (n=10)	0,4495
Baseline Anti thyroglobulin (UI/ml)	19.00 (11.60 - 19.00) (n=172)	16.50 (11.08 – 19.00) (n=90)	19.00 (13.25 – 19.00) (n=82)	0.2779	19.00 (12.40 - 19.00) (n=161)	13.00 (2.19 - 17.93) (n=11)	0,0895
Diseases duration (months)	16.50 (8.00 - 30.75) (n=254)	13.00 (7.00 – 45.50) (n=131)	21.00 (9.00 – 78.00) (n=123)	0.0148	17.00 (8.00 – 60.00) (n=230)	11.00 (7.25 – 39.00) (n=24)	0,2896
Angioedema (%)	52.52 (n=257)	51.12 (n=133)	54.03 (n=124)	0.6412	52.36 (n=233)	54.17 (n=24)	0.8660
CindU (%)	35.79 (n=257)	30.08 (n=133)	41.94 (n=124)	0.0475	35.19 (n=233)	41.67 (n=24)	0.5287
Immunosuppressive therapy (%)	37.74 (n=257)	39,10 (n=133)	36.30 (n=124)	0.6426	38.63 (n=233)	29.17 (n=24)	0.3626
Baseline UAS7	24.00 (18.00 - 30.75) (n=226)	24.00 (17.00 – 31.00) (n=113)	24.00 (19.00 – 30.00) (n=113)	0.8826	24.00 (18.00 – 31.00) (n=205)	21.00 (20.00 – 28.00) (n=21)	0,9009
Baseline UCT	4.50 (2.00 - 8.00) (n=170)	5.00 (2.00 – 8.00) (n=88)	4.00 (2.00 – 8.00) (n=82)	0.3514	5.00 (2.00 – 8.00) (n=153)	4.00 (3.00 – 5.00) (n=17)	0,4217
Previous updosing (%)	28.64 (n=256)	15.04 (n=133)	30.08 (n=123)	0.0038	19.83 (n=232)	45.83 (n=24)	0.0035
Time until PR (months)	2.00 (1.00 - 4.00) (n=255)	2.00 (1.00 – 4.00) (n=133)	2.00 (1.00 – 4.00) (n=122)	0.5191	2.00 (1.00 - 4.00) (n=231)	3.00 (1.75 – 4.5) (n=24)	0,0677
CR pre tapering (%)	89.88 (n=257)	94.74 (n=133)	84.68 (n=124)	0.0075	91.42 (n=233)	75.00 (n=24)	0.0111
Treatment at 300mg/4w (months)	7.00 (4.00 - 13.00) (n=257)	7.00 (4.00 - 12.00) (n=133)	7.00 (4.50 – 14.00) (n=123)	0.5558	7.00 (4.00 – 12.00) (n=232)	10.00 (4.75 – 23.00) (n=24)	0,1579